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Valve Repair With the MitraClip in Patients With
Versus Without Atrial Fibrillation
Juliëtte F. Velu, MSca, Friso A. Kortlandt, MDb, Tom Hendriks, MDc, Remco A.J. Schurer, MDc,
Ad J. van Boven, MD, PhDd, Karel T. Koch, MD, PhDa, M. Marije Vis, MD, PhDa,
Jose P. Henriques, MD, PhDa, Jan J. Piek, MD, PhDa, Ben J.L. Van den Branden, MD, PhDe,
Jeroen Schaap, MD, PhDe, Benno J. Rensing, MD, PhDb, Martin J. Swaans, MD, PhDb,
Berto J. Bouma, MD, PhDa, Jan A.S. Van der Heyden, MD, PhDb, and Jan Baan Jr, MD, PhDa,*
Percutaneous mitral valve repair with the MitraClip is an established treatment for
patients with mitral regurgitation (MR) who are inoperable or at high risk for surgery.
Atrial Fibrillation (AF) frequently coincides with MR, but only scarce data of the influ-
ence of AF on outcome after MitraClip is available. The aim of the current study was to
compare the clinical outcome after MitraClip treatment in patients with versus without
atrial fibrillation. Between January 2009 and January 2016, all consecutive patients
treated with a MitraClip in 5 Dutch centers were included. Outcome measures were
survival, symptoms, MR grade, and stroke incidence. In total, 618 patients were treated
with a MitraClip. Patients with AF were older, had higher N-terminal B-type natriuretic
peptide levels, more tricuspid regurgitation, less often coronary artery disease and a
better left ventricular function. Survival of patients treated with the MitraClip was
similar for patients with AF (82%) and without AF (non-AF; 85%) after 1 year (p = 0.30),
but significantly different after 5-year follow-up (AF 34%; non-AF 47%; p = 0.006). After
1 month, 64% of the patients with AF were in New York Heart Association class I or II, in
contrast to 77% of the patients without AF (p = 0.001). The stroke incidence appeared not
to be significantly different (AF 1.8%; non-AF 1.0%; p = 0.40). In conclusion, patients
with AF had similar 1-year survival, MR reduction, and stroke incidence compared with
non-AF patients. However, MitraClip patients with AF had reduced long-term survival
and remained more symptomatic compared with those without AF. © 2017 The Authors.
Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/). (Am J Cardiol 2017;120:2035–2040)
Percutaneous mitral valve repair with the MitraClip is an
established treatment for patients with mitral regurgitation
(MR) who are inoperable or at high risk for surgery.1–3 Atrial
fibrillation (AF) frequently coincides with MR.4 AF is common
in the general population, with a prevalence increasing with
age.5–7 Population-based studies indicate an impaired long-
term survival and an increased risk of stroke in patients with
AF compared with patients without AF (or non-AF).8–11 In
some studies, the outcome of surgical mitral valve repair in
patients with AF was similar compared with patients without
AF,12,13 in contrast to some surgical studies that reported worse
outcomes for patients with AF.14–16 Conflicting results have
also been reported about the impact of AF on the outcome
of MitraClip implantation.17–20 The aim of the current study
was to compare in a large-scale study the clinical outcome
after percutaneous mitral valve repair with the MitraClip in
patients with versus without atrial fibrillation.
Methods
Between January 2009 and January 2016, all 618 con-
secutive patients treated with a MitraClip in 5 Dutch centers
were included. Preprocedural evaluation included physical ex-
amination, electrocardiography, transthoracic echocardiography
(TTE), transesophageal echocardiography, and laboratory mea-
surements. Patients were judged in a heart team consisting
of an interventional cardiologist, an imaging cardiologist, and
a cardiac surgeon. All patients had symptomatic MR and were
rejected for surgery. Main exclusion criteria for MitraClip treat-
ment were an unsuitable mitral valve anatomy or a life
expectancy assessed as below 12 months due to severe co-
morbidities. Thirty-nine patients who did not receive a
MitraClip during the implantation procedure were excluded
from the analyses.
The MitraClip procedure has previously been described.1,21
The procedure was performed under general anesthesia, using
aDepartment of Cardiology, Academic Medical Center, Amsterdam, The
Netherlands; bDepartment of Cardiology, St. Antonius Hospital, Nieuwegein,
The Netherlands; cDepartment of Cardiology, University Medical Center Gron-
ingen, Groningen, The Netherlands; dDepartment of Cardiology, Medical
Center Leeuwarden, Leeuwarden, The Netherlands; and eDepartment of Car-
diology, Amphia Hospital, Breda, The Netherlands. Manuscript received June
8, 2017; revised manuscript received and accepted August 8, 2017.
See page 2039 for disclosure information.
*Corresponding author: Tel: +31 20 566 6555; fax: +31 20 696 2609.
E-mail address: j.baan@amc.nl (J. Baan).
0002-9149/© 2017 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
https://doi.org/10.1016/j.amjcard.2017.08.022
www.ajconline.org
fluoroscopic and transesophageal echocardiographic guid-
ance. The results of MitraClip implantation were evaluated
by TTE at discharge and during follow-up. All patients gave
their written informed consent. The study complied with the
ethical guidelines of the 1975 Declaration of Helsinki re-
garding investigation in humans.
The baseline characteristics of 618 patients were entered
into the dedicated, prospective web-based database. All pa-
tients were invited for clinical evaluation and TTE at 1 month,
6 months, and 12 months after MitraClip implantation. The
stroke incidence was documented over the full follow-up
period. Symptoms of dyspnea were quantified using the New
York Heart Association (NYHA) classification. MR sever-
ity was graded as none, mild (1), moderate (2), moderate to
severe (3), or severe (4) by experienced echocardiographers.
Patients were followed-up until either their death, or until
March 1, 2016.
Continuous variables were expressed as mean ± standard
deviation or as median and interquartile range. Categorical
variables were presented as absolute numbers and percent-
ages. Survival was described using the Kaplan-Meier method.
Multivariable Cox regression, using stepwise forward selec-
tion, was performed to analyze the association of clinical
characteristics with survival, expressed as hazard ratio (HR)
with 95% confidence interval (CI) and p values. Confounders-
adjusted logistic regression analysis was used for binary
data and expressed as odds ratios with 95% CI and p values.
McNemar’s test was used to compare paired categorical
data. Chi-square testing was used to compare unpaired cat-
egorical data. An unpaired t test was used to compare
continuous variables when normally distributed and a Mann-
Whitney U test when not normally distributed. Differences
were considered statistically significant at p values <0.05.
All statistical analyses were performed using SPSS soft-
ware (IBM SPSS Statistics version 23, IBM Corp, Armonk,
New York).
Results
In total, 618 patients were treated with the MitraClip. Base-
line characteristics were generally comparable between patients
with and without AF (Table 1), except that patients with AF
were older (p <0.001), had higher levels of N-terminal pro-
B-type natriuretic peptide (NT-proBNP) (p <0.001), and had
more often a tricuspid regurgitation grade 4 (p = 0.045). Fur-
thermore, patients without AF had more often coronary artery
disease (p = 0.02) and an impaired left ventricular function
(p <0.001).
The number of implanted MitraClips was similar for
patients with and without AF (p = 0.19). Summarizing, 351
(57%) patients were treated with 1 MitraClip and 267 (43%)
with ≥2 MitraClips. The use of ≥2 MitraClips changed over
time, with 29% in the first one-third and 54% in the last
one-third of the patients. MR grade 1 or 2 after MitraClip
procedure was 79% for patients with AF and 82% for pa-
tients without AF (p = 0.36). The recurrent MR rate, defined
as recurring to MR grade 3 or 4 during the first 12 months,
was also similar for patients with (32%) and without AF
(30%) (p = 0.74).
The median follow-up duration was 1.8 years. The sur-
vival estimate after 1 year was similar for patients treated with
the MitraClip with AF (82%) and without AF (85%) (p = 0.30).
However, the survival estimate after 5 years was signifi-
cantly different (AF 34%, non-AF 47%, p = 0.006) (Figure 1).
Table 1
Baseline characteristics
Variable All patients (n = 618) Atrial fibrillation p value
No (n = 292) Yes (n = 326)
Age at procedure (years) 74 ± 11 71 ± 11 76 ± 9 <0.001
Men 353 (57%) 168 (58%) 185 (57%) ns
Logistic European System for Cardiac Operative Risk Evaluation (%) 19.6 ± 14.2 19.3 ± 14.1 19.8 ± 14.3 ns
Chronic obstructive pulmonary disease 128 (21%) 64 (22%) 64 (20%) ns
Coronary artery disease 357 (58%) 183 (63%) 174 (53%) 0.02
Cardiac implantable electronic devices 192 (31%) 94 (32%) 98 (30%) ns
Diabetes Mellitus 142 (23%) 73 (25%) 69 (21%) ns
Hypertension 322 (52%) 146 (50%) 176 (54%) ns
Previous coronary artery bypass graft 185 (30%) 91 (31%) 94 (29%) ns
Previous percutaneous coronary intervention 178 (29%) 90 (31%) 88 (27%) ns
Previous stroke 71 (12%) 38 (13%) 33 (10%) ns
Previous valve surgery 43 (7%) 15 (5%) 28 (9%) ns
New York Heart Association class ≥III/IV 538 (87%) 250 (86%) 288 (88%) ns
N-terminal pro-B-type natriuretic peptide (ng/L) 1642 (600–3669) 1135 (417–3253) 1905 (864–4072) <0.001
Estimated glomerular filtration rate (ml/min/1.73 m2) 56 ± 23 58 ± 24 54 ± 22 ns
Echocardiographic variables
Mitral regurgitation grade 4 406 (66%) 203 (70%) 203 (62%) ns
Tricuspid regurgitation grade 4 62 (10%) 22 (8%) 40 (12%) 0.045
Mitral regurgitation etiology ns
Degenerative 126 (20%) 55 (19%) 71 (22%)
Functional 456 (74%) 225 (77%) 231 (71%)
Mixed 36 (6%) 12 (4%) 24 (7%)
Impaired left ventricular function (<30%) 227 (37%) 130 (45%) 97 (30%) <0.001
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Multivariable Cox regression showed that age ≥80 years (HR
2.8, 95% CI 1.4 to 5.7), male gender (HR 1.4, 95% CI 1.0
to 1.9), and NT-proBNP ≥5,000 ng/L (HR 3.4, 95% CI 2.1
to 5.6) were significant predictors of long-term survival,
whereas AF was not a multivariable long-term predictor
(Table 2).
The amount of patients in NYHA class I or II was similar
at baseline (AF 12%, non-AF 14%, p = 0.31). After 1 month,
64% of the patients with AF was in NYHA class I or II, in
contrast to 77% of the patients without AF (p = 0.001)
(Figure 2). But the improvement of patients with AF, from
12% in NYHA class I or II to 64%, was still significant
(p = 0.001). Logistic regression showed that AF remained a
significant predictor for NYHA III or IV after 1 month (odds
ratio 1.7, 95% CI 1.0 to 2.8, p = 0.045), even after adjust-
ment for age, gender, chronic obstructive pulmonary disease,
tricuspid regurgitation, NYHA at baseline, left ventricular func-
tion, MR at discharge, and MR recurrence.
The stroke incidence appeared not to be significantly dif-
ferent with 1.8% for patients with AF and 1.0% for patients
without AF (p = 0.40). No determinants for stroke could be
identified. Incidence of ischemic and hemorrhagic strokes and
stroke-free survival curves of patients with and without AF
treated with MitraClip are shown in the supplementary ma-
terials (Supplementary Table S1 and Supplementary
Figure S1).
Discussion
Patients with AF had MitraClip implantations benefits
similar to non-AF patients in terms of 1-year survival.
However, the majority of AF patients remained more symp-
tomatic than patients without AF. Therefore, expectations in
symptom reduction in AF patients should be reduced.
Current findings regarding survival were influenced by dif-
ferences in baseline characteristics. Patients with AF were on
average 5 years older than patients without AF and had higher
levels of NT-proBNP. AF appeared not be a long-term pre-
dictor in multivariate analysis, in contrast to age and NT-
proBNP. No differences in estimated 5-year survival were
shown per subgroup after stratification of the patients by age
(Supplementary Table S2). Regarding the effect of the
MitraClip on the symptoms, it can be stated that logistic re-
gression, however, showed that AF remained a significant
predictor for NYHA III or IV after 1 month. Many other con-
founding factors are present, and AF is often a marker for
more advanced heart disease and heart failure in general. AF
can be a consequence of MR or, conversely, long-standing
AF can lead to left atrial and mitral annular dilation, which
causes MR. In regard to former published studies, our pa-
tients were comparable in baseline characteristics, for example,
in age, gender, Logistic European System for Cardiac Op-
erative Risk Evaluation (EuroSCORE), and left ventricular
Figure 1. Survival after MitraClip implantation. The survival of patients with (n = 326) and without (n = 292) AF treated with MitraClip. AF = atrial fibrillation.
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ejection fraction.17,18,20 However, the mean age in the
Endovascular Valve Edge-to-Edge Repair Study (EVEREST
II) study was 67 years, and the majority of their patients had
degenerative MR.17 The mean age in our cohort was 74 years
and the majority of our patients had functional MR, with no
significant differences between patients with or without AF.
A similar percentage of AF patient had degenerative mitral
valve disease compared with non-AF patients, as was pro-
cedural success rates. In accordance with previous studies,
procedural success was equal.17,18,20
Most previous studies limited their analyses to 1-year sur-
vival after MitraClip treatment. Two studies showed similar
1-year survival rates for patients with and without AF,17,18 while
1 study reported worse 1 year survival for patients with AF.20
The differences in age and etiology between the EVEREST
II study and our study can be an explanation for the differ-
ence in survival after MitraClip implantation. Factors as age
appeared to be more important for life expectancy than AF.
A previous study, based on the same population, proposed a
risk model based on multiple factors of the baseline charac-
teristics to enhance the patient selection.22 A comparison of
outcomes with previous studies is visualized in Table 3. Median
follow-up duration in the current literature varies between 6
months and 1 year; our median follow-up was 1.8 years.
Patients with AF remained more symptomatic after
MitraClip treatment compared with those without AF. None-
theless, symptoms were reduced significantly after MitraClip
treatment. It is difficult to investigate whether symptoms origi-
nated from the AF, the MR, or both as studies comparing rate-
control versus rhythm-control showed that presence of AF was
associated with worse a NYHA class and that NYHA class
worsened over time.23 There are conflicting findings on
symptom reduction in patients with or without AF after
MitraClip treatment (Table 3). The EVEREST II demon-
strated that a significantly different percentage of patients were
in NYHA class I or II at 12 months, being more present in
people without AF.17 By contrast, another study showed a
similar improvement in NYHA class.18 Besides, the
TRAnscatheter Mitral valve Interventions (TRAMI) study also
concluded that the majority of the patients were in NYHA
class I or II after 1 month, but this was not statistically com-
pared and seemed different (AF 58%, non-AF 71%).20
Explanations for discrepancies in MitraClip literature regarding
Table 2
Predictors of mortality in multivariable analysis
Variable All patients Multivariable analysis
(n = 618) HR (95% CI) p value
Age at procedure (years) 74 ± 11
<60 59 (10%) 1
60–69 122 (20%) 1.4 (0.7–3.0) 0.39
70–79 233 (38%) 2.7 (1.3–5.3) 0.005
≥80 204 (33%) 2.8 (1.4–5.7) 0.003
Men 353 (57%) 1.4 (1.0–1.9) 0.037
Atrial fibrillation 326 (53%) 0.21




<500 72 (12%) 1
500–1999 131 (21%) 1.3 (0.8–2.1) 0.32
2000–4999 170 (28%) 1.6 (1.0–2.7) 0.052






30–44 218 (35%) 0.80
45–59 159 (26%) 0.26
≥60 103 (17%) 0.137
Mitral regurgitation grade 4 406 (66%) 1.6 (1.1–2.2) 0.009




Figure 2. NYHA class after MitraClip implantation. The NYHA class after the MitraClip implantation of patients with (n = 326) and without (n = 292) AF.
AF = atrial fibrillation; NYHA = New York Heart Association.
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the mortality and symptom reduction may be explained by
the extreme heterogeneity of the patient population. A
MitraClip treatment is suitable both for old and vital as well
as for young and diseased patients.
Stroke incidence during follow-up appeared not to be sig-
nificantly different between AF and non-AF patients in
our cohort. This finding is important because of concerns re-
garding thrombus formation after MitraClip implantation.
Current literature emphasizes the risk of thrombus forma-
tion after describing a case with acute left atrial spontaneous
echocardiographic contrast and suspicious thrombus forma-
tion during a MitraClip procedure.24
This study was limited by the fact that the data were col-
lected by several physicians. Despite the strict definitions, the
interpretation of variables may differ. AF was not subclas-
sified because the registry did not include differentiation in
AF-type. Rehospitalization rates were not investigated because
patients were often rehospitalized peripherally. The
echocardiographic data were not adjudicated in a core labo-
ratory, but analyses were conducted by highly experienced
physicians. Some known predictors of mortality or symp-
toms were not included, which could lead to confounding.
Patients with AF remained more symptomatic after
MitraClip treatment compared with non-AF patients. However,
the majority of patients with AF still had symptom reduc-
tion after MitraClip treatment. One-year survival, MR
reduction, and stroke incidence were similar in patients with
AF to patients without AF detected. Therefore, AF patients
should not be denied treatment with MitraClip, although ex-
pectations in symptom reduction should be reduced.
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